Status:
COMPLETED
Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]
Lead Sponsor:
Pfizer
Conditions:
Carcinoma, Renal Cell, Advanced
Lymphoma, Mantle-Cell
Eligibility:
All Genders
18-99 years
Brief Summary
The purpose of this registry is to obtain a general view as regards efficacy, tolerability and safety issues of the Torisel®, Sutent®, and/or Inlyta® therapies in patients with advanced renal cell car...
Detailed Description
Treatment of the metastatic renal cell carcinoma (mRCC) has experienced fundamental changes within a very short period of time. In the past few years, introduction of various new substances for the tr...
Eligibility Criteria
Inclusion
- Patients with proven tumor of RCC, MCL or GIST by histology.
- Informed consent signed by patient.
Exclusion
- Pregnancy
Key Trial Info
Start Date :
February 13 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 28 2021
Estimated Enrollment :
1520 Patients enrolled
Trial Details
Trial ID
NCT00700258
Start Date
February 13 2008
End Date
December 28 2021
Last Update
September 23 2024
Active Locations (77)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitätsklinikum Ulm
Ulm, Baden-Wurttemberg, Germany, 89070
2
Dr. med. Harald Held
Neumünster, Schleswig-Holstein, Germany, 24534
3
Dr. med. Hans Wilhelm Duebbers
Ahaus, Germany, 48683
4
Dr. Ludwig Fischer von Weikersthal
Amberg, Germany, 92224